The Aperio Blog
PharmaVoice Features Cari Kniola on Market Growth Factors and Barriers in Decentralized Clinical Trials
October 5, 2021
Decentralized Clinical Trials may be one of the hottest buzzwords in clinical research right now, but Decentralized Clinical Trials are not new. In fact, technologies that support aspects of remote trials – such as wearables, eCOA, eConsent and Electronic health Records -have been around for awhile.
According to PharmaVoice’s recent Pulse Report on Decentralized Clinical Trials, “what is transformational is the combination of multiple technologies to seamlessly knit together a better patient journey. ”
With the market set to explode to more than $1.63 billion by 2027, read what Aperio’s Director of Corporate Strategy Cari Kniola and other industry thought leaders had to say about market growth factors and barriers to overcome in Decentralized Clinical Trials in PharmaVoice’s October issue of the Pulse Report. Read here.
About Aperio Clinical Outcomes
Aperio Clinical Outcomes provides full, customizable clinical research services across multiple therapeutic areas. Dedicated to transparent interactions with clients, Aperio also offers consulting services in Quality Assurance, Strategic Resourcing, and practical application of the latest Clinical Trial Technology.
In an industry flooded with data, metrics and technology, Aperio remains steadfastly focused on the most important part of the process: people. From start-up to close out and every point in between, Aperio works with its partners to deliver outcomes that will improve patient care and save lives.
Aperio Clinical Outcomes.
We make it clear.
